Evaluation of antiarrhythmic drug efficacy in patients with an ICD: Unlimited potential or replete with complexity and problems?

Journal of Cardiovascular Electrophysiology

Volumn 10, Issue 11, 1999, Pages 1534-1549

  Pratt, Craig M ^a   Camm, A John ^b   Bigger Jr , J Thomas ^c   Breithardt, Günter ^d   Campbell, Ronald W F ^e   Epstein, Andrew E ^f   Kappenberger, Lukas J ^g   Kuck, Karl heinz ^h   Pocock, Stuart ⁱ   Saksena, Sanjeev ^j   Waldo, Albert L ^k  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e FREEMAN HOSPITAL   (United Kingdom)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h DEPARTMENT OF CARDIOLOGY   (Germany)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^j Eastern Institute General Hospital   (United States)

^k CASE WESTERN RESERVE UNIVERSITY   (United States)

more..

Author keywords

Antiarrhythmic agents; Implantable cardioverter defibrillator

Indexed keywords

ANTIARRHYTHMIC AGENT;

ANTIARRHYTHMIC ACTIVITY; CLINICAL RESEARCH; CLINICAL TRIAL; DEFIBRILLATOR; DRUG EFFICACY; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

EID: 0032753791     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1999.tb00212.x     Document Type: Review

References (70)

1. 1. Siebels J, Cappato R, Ruppel R, et al, for the CASH Investigators: Preliminary results of the Cardiac Arrest Study Hamburg (CASH). Am J Cardiol 1993;72:109F-113F.
2. 2. Siebels J, Kuck KH: Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J 1994;127:1139-1144.
3. 3. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators: A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-1583.
4. 4. Moss AJ, Hall J, Cannom DS, et al, for the Multicenter Automatic Defibrillator Implantation Trial Investigators: Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmias. N Engl J Med 1996;335:1933-1940.
5. 5. Hohnloser SH, Singh BN: Proarrhythmia with Class III antiarrhythmic drugs: Definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 1995;6: 920-936.
6. 6. Sagie A, Strasberg B, Kusniec J, et al: Rapid suppression of flecainide induced incessant ventricular tachycardia with high dose intravenous amiodarone. Chest 1988;93:879-880.
7. 7. Gottlieb CD, Horowitz LN: Potential interactions between antiarrhythmic medication and the automatic implantable cardioverter defibrillator. PACE, 1991;14: 898-904.
8. 8. Echt DS, Gremillion ST, Lee JT, et al: Effects of procainamide and Iidocaine on defibrillation energy requirements in patients receiving implantable cardioverter defibrillator devices. J Cardiovasc Electrophysiol 1994;5:752-760.
9. 9. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
10. 10. The Cardiac Arrhythmia Suppression Trial II Investigators: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-233.
11. 11. Waldo AL, Camm AJ, deRuyter H, et al, for the SWORD Investigators: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after myocardial infarction. Lancet 1996;348:7-12.
12. 12. Pratt CM, Camm AJ, Cooper W, et al, for the SWORD Investigators: Mortality in the survival with oral d-sotalol (SWORD) trial: Why did patients die? Am J Cardiol 1998;81:869-876.
13. 13. Julian DG, Camm AJ, Frangin G, et al, for the European Myocardial Infarct Amiodarone Trial Investigators: Randomised trial of effect of amiodarone on mortality in patient with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349:667-674.
14. 14. Janse MJ, Malik M, Camm AJ, et al: Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (the European Myocardial Infarct Amiodarone Trial). Eur Heart J 1998;19:85-95.
15. 15. DIAMOND Study Group: Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: Rationale, design and patient characteristics of the DIAMOND studies. Clin Cardiol 1997;20:704-710.
16. 16. The DIAMOND Study Group: Dofetilide a new class III antiarrhythmic drug prevents atrial fibrillation in patients with congestive heart failure in normal sinus rhythm. Results of the DIAMOND-CHF study. (Abstract) J Am Coll Cardiol 1999;33:132A.
17. 17. Connolly SJ, Gent M, Roberts RS, et al: Canadian Implantable Defibrillator Study (CIDS): Study design and organization. Am J Cardiol 1993;72:103F-108F.
18. 18. Bigger JT Jr: Prophylactic use of implantable cardiac defibrillators in patients at risk of ventricular arrhythmias after coronary artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) patch trial investigators. N Engl J Med 1997;337:1569-1575.
19. 19. Buxton AH, Lee KL, DeCarlo L, et al: Nonsustained ventricular tachycardia in coronary artery disease: Relation to inducible sustained ventricular tachycardia. MUSTT Investigators. Ann Intern Med 1996;125:35-39.
20. 20. Bardy GH, Lee KL, Mark DB, and the SCD-HeFT Pilot Investigators: The Sudden Cardiac Death in Heart Failure Trial: Pilot study. (Abstract) PACE 1997;20:1148.
21. 21. Moss AJ, Cannom DS, Dubert JP, et al, for the MADIT II Investigators: Multicenter Automatic Defibrillator Implantation Trial II (MADIT II): Design and clinical protocol. Ann Noninvas Electrocardiol 1999;4:83-91.
22. 22. Nisam S, Mower M: ICD trials: An extraordinary means of determining patient risk? PACE 1998;21: 1341-1346.
23. 23. Hinkle LE, Thaler HT: Clinical classification of cardiac deaths. Circulation 1982;65:457-464.
24. 24. Kim SG, Fogoros RN, Furman S, et al: Standardized reporting of ICD patient outcome: The report of a North American Society of Pacing and Electrophysiology Policy Conference, February 9-10, 1993. PACE 1993; 16:1358-1362.
25. 25. Greene HL: The CASCADE Study: Randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. CASCADE Investigators. Am J Cardiol 1993; 72:70F-74F.
26. 26. Dolack GL: Clinical predictors of implantable cardioverter-defibrillator shocks (results of the CASCADE trial). Cardiac Arrest in Seattle, Conventional versus Amiodarone Drug Evaluation. Am J Cardiol 1994;73: 237-241.
27. 27. The CASCADE Investigators: Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol 1993;72:280-287.
28. 28. Böcker D, Block M, Isbruch F, et al: Comparison of frequency of aggravation of ventricular tachyarrhythmias after implantation of automatic defibrillators using epicardial versus nonthoracotomy lead systems. Am J Cardiol 1993;71:1064-1068.
29. 29. Echt DS, Leibson PR, Mitchell B, et al, and the CAST Investigators: Mortality and morbidity in patients receiving encainide, flecainide or placebo. N Engl J Med 1991;324:781-788.
30. 30. Grimm W, Flores BF, Marchlinski FE: Symptoms and electrocardiographically documented rhythm preceding spontaneous shocks in patients with implantable cardioverter defibrillalor. Am J Cardiol 1993;71:1415-1418.
31. 31. Hook BG, Callans DJ, Kleiman RB, et al: Implantable cardioverter defibrillator therapy in the absence of significant symptoms: Rhythm diagnosis and management aided by stored electrogram analysis. Circulation 1993; 87:1897-1906.
32. 32. Kou WH, Calkins H, Lewis RR, et al: Incidence of loss of consciousness during automatic implantable cardioverter-defibrillator shocks. Ann Intern Med 1991;115: 942-945.
33. 33. Bansch D, Brunn J, Castrucci M, et al: Syncope in patients with an implantable cardioverter defibrillator: Incidence, prediction and implications for driving restrictions, J Am Coll Cardiol 1998;31:608-615.
34. 34. Wietholt D, Block M, Isbruch F, et al: Clinical experience with antitachycardia pacing and improved detection algorithms in a new implantable cardioverter defibrillator. J Am Coll Cardiol 1993;21:885-894.
35. 35. Bayes de Luna A, Coumel P, Leclercq JF: Ambulatory sudden cardiac death: Mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989;117:151-159.
36. 36. Exner DV, Gillis AM, Sheldon RS, et al: Telemetry documented, pace terminable ventricular tachycardia in patients with ventricular fibrillation. Am J Cardiol 1998;81:235-238.
37. 37. Böcker D, Block M, Isbruch F, et al: Do patients with an implantable defibrillator live longer? J Am Coll Cardiol 1993;21:1638-1644.
38. 38. Böcker D, Bansch D, Henecke A, et al: Potential benefit from implantable cardioverter defibrillator therapy in patients with and without heart failure. Circulation 1998;98:1636-1643.
39. 39. Stevens SK, Haffajee CI, Naccarelli GV, et al: Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter defibrillators. J Am Coll Cardiol 1996;28:418-422.
40. 40. Jung W, Manz M, Pizzulli L, et al: Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol 1992;70:1023-1027.
41. 41. Movsowitz C, Marchlinski FE: Interactions between implantable cardioverter-defibrillators and class III agents. Am J Cardiol 1998;82:411-481.
42. 42. Tacker WA, Niebauer MJ, Babbs CF, et al: The effect of newer antiarrhythmic drugs on defibrillation threshold. Crit Care Med 1980;8:177-180.
43. 43. Wang M, Dorian P: dL and d-sotalol decrease defibrillation energy requirements. PACE 1989;12:1522-1529.
44. 44. Dorian P, Newman D: Effect of sotalol on ventricular fibrillation and defibrillation in humans. Am J Cardiol 1993;72:72A-79A.
45. 45. Jung W, Manz M, Pizzulli L, et al: Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol 1992;70:1023-1027.
46. 46. Gillberg JM, Olson WH, Bardy GH, et al: Electrogram width algorithm for discrimination of supraventricular rhythm from ventricular tachycardia. (Abstract) PACE 1994;17:866.
47. 47. Ruetz LL, Bardy GH, Mitchell LB, et al: Clinical evaluation of electrogram width measurements for automatic ventricular tachycardia. (Abstract) PACE 1996; 19:582.
48. 48. Osswald S, Cron TA, Sterns L, et al: New ICD technologies: First clinical experience with dual chamber sensing for differentiation of supraventricular arrhythmias. PACE 1998;21:292-295.
49. 49. Bardy GH, Olson W, Barnes J, et al: Ventricular fibrillation cycle length spectrum: Measured values in comparison to sensed values as a function of ICD sensitivity setting. (Abstract) PACE 1993;16:585.
50. 50. Bardy GH, Ivey T, Stewart R, et al: Failure of the automatic implantable cardioverter defibrillator to detect ventricular fibrillation. Am J Cardiol 1986;58: 1107-1108.
51. 51. Cohen TJ, Liem LB: Biosensor applications to antitachycardia devices. PACE 1991;14:322-328.
52. 52. Prevot E, Vesin JM, Schmidiager H, et al, on behalf of the HRVF study investigators: Analysis of heart rate variability at the onset of spontaneous ventricular tachyarrhythmias as retrieved from a defibrillator. Eur Heart J 1977;18:592.
53. 53. Vetter R, Celka P, Vesin JM, et al: Subband modeling of the human cardiovascular system: New insights into cardiovascular regulation. Ann Biomed Eng 1998;26: 293-307.
54. 54. Cohen TJ, Liem LB: A hemodynamically responsive antitachycardia system. Development and basis for design in humans. Circulation 1990:82:394-406.
55. 55. Kaye GC, Astridge P, Perrins J: Tachycardia recognition and diagnosis from changes in right atrial pressure wave-form - A feasibility study. PACE 1991;14:1384-1392.
56. 56. Wood MA, Ellenbogen KA, Kapadia K, et al: Comparison of right ventricular impedance, pulse pressure and maximal dP/dt for determination of hemodynamic stability of ventricular arrhythmias associated with coronary artery disease. Am J Cardiol 1990;66:575-582.
57. 57. Krahn AD, Klein GJ, Norris C, et al: The etiology of syncope in patients with negative tilt table and electrophysiological testing. Circulation 1995;92:1819-1824.
58. 58. Pratt CM, Greenway PS, Schoenfeld MH, et al: An exploration of the precision of classifying sudden cardiac death: Implications for the interpretation of clinical trials. Circulation 1996;93:519-524.
59. 59. Pocock SJ: Clinical trials with multiple outcomes: A statistical perspective. Control Clin Trials 1997;18:530-545.
60. 60. Pocock SJ, Geller NL, Tsiatis AA: The analysis of multiple endpoints in clinical trials. Biometrics 1987; 43:487-498.
61. 61. O'Brien PC: Procedures for comparing samples with multiple endpoints. Biometrics 1984;40:1079-1087.
62. 62. Raviele A, Bongiorni MG, Brignole M, et al: Which strategy is "best" after myocardial infarction? The Beta-blocker Strategy Plus Implantable Cardioverter Defibrillator Trial: Rationale and study design. Am J Cardiol 1999;83:104D-111D.
63. 63. Wever EFD, Hatter RNW, van Capelle FJI, et al: Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in post-infarct study death survivors. Circulation 1995;91:2195-2203.
64. 64. Myerburg RJ, Luceri RM, Thurer R, et al: Time to first shock and clinical outcome in patients receiving an implantable cardioverter-defibrillator. J Am Coll Cardiol 1989;4:508-514.
65. 65. Huang SKS, Tan de Guzman WLT, Chenarides JG, et al: Effects of long-term amiodarone therapy on the defibrillation threshold and the rate of shocks of the implantable cardioverter-defibrillator. Am Heart J 1991;122:720-727.
66. 66. Grimm W, Flores BT, Marchlinski FE: Shock occurrence and survival in 241 patients with implantable cardioverter-defibrillator therapy. Circulation 1993;7: 1880-1888.
67. 67. Kelly PA, Cannom DS, Garan H, et al: The automatic implantable cardioverter-defibrillator: Efficacy, complications and survival in patients with malignant ventricular arrhythmias. J Am Coll Cardiol 1988;11:1278-1286.
68. 68. Saksena S, Poczobutt-Johanos M, Castle LW, et al: Long-term multicenter experience with a second-generation implantable pacemaker-defibrillator in patients with malignant ventricular tachyarrhythmias. The Guardian Multicenter Investigators Group. J Am Coll Cardiol 1992;19:490-499.
69. 69. Echt DS, Armstrong K, Schmidt P, et al: Clinical experience, complications, and survival in 70 patients with the automatic implantable cardioverter-defibrillator. Circulation 1985;71:289-296.
70. 70. Pacifico A, Hohnloser SH, Williams JH, et al, for the d,1-Sotalol Implantable Cardioverter-Defibrillator Study Group: Prevention of implantable-defibrillator shocks by treatment with sotalol. N Engl J Med 1999;340:1855-1862.